Press Releases

,

Prolong Pharmaceuticals Announces Completion of Enrollment in Phase II Study of SANGUINATE® in the Treatment of Sickle Cell Disease Patients with Vaso-Occlusive Crisis in an Ambulatory Setting

Prolong Pharmaceuticals announced today that it has completed enrollment in its Phase II study to evaluate SANGUINATE® in the treatment of vaso-occlusive crisis in patients with sickle cell disease (SCD). SANGUINATE® is a first-in-class oxygen-delivery agent that is in development to treat localized and systemic hypoxia...
,

Biosimilars & Biobetters, Interview Series for 2017 -- An Interview with Glenn Kazo, President from Prolong Pharmaceuticals.

An Interview with Glenn Kazo, President from Prolong Pharmaceuticals. With over 25 years of experience, Glenn Kazo is the President and Chief Operating Officer of Prolong Pharmaceuticals LLC, a privately held company with portfolio of hematology and oncology products in clinical development. Over the last decade Kazo has been very active in the advancement of Biosimilars and BioBetters, both as an industry speaker and in leading several drug development programs...
,

New Research Suggests SANGUINATE™ Reduces the Number of Sickled Red Blood Cells in Patients with Vaso-Occlusive Crisis

SOUTH PLAINFIELD, N.J., May 2, 2017 /PRNewswire/ -- SANGUINATE™, the only investigational biopharmaceutical product currently in clinical development for the treatment of multiple comorbidities of sickle cell disease (SCD), is effective in returning red blood cells to a more normal morphology (shape) in patients experiencing vaso-occlusive crisis (VOC)...
,

Prolong Pharmaceuticals Presents Data on Toxicology, Pharmacokinetics and Pharmacodynamics of ANF-RHO™

Unique activity Noted in Drug: Prolong Pharmaceuticals, LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities announced today that it has presented data on the toxicology, pharmacokinetic and pharmacodynamic profile of its novel anti-neutropenia drug, ANF-RHO.
,

Prolong Pharmaceuticals Hosts Workshop at the Society for Blood Advancement

Prolong Pharmaceuticals presented at the 2016 Society for Blood Advancement (SABM) meeting in Grand Rapids Michigan. The Workshop entitled Clinical Use of SANGUINATE in Patients for Whom Blood is Not an Option provided an overview of the use of SANGUINATE followed by the presentation of a case report of a patient who received SANGUINATE for life threatening anemia.
,

Prolong Pharmaceuticals Hosts Lunch & Learn and Announces Launch of SCDTrialMap.com at the 44th Annual Convention of the Sickle Cell Disease Association of America

Prolong Pharmaceuticals Hosts Lunch & Learn and Announces Launch of SCDTrialMap.com at the 44th Annual Convention of the Sickle Cell Disease Association of America.

PROLONG PHARMACEUTICALS JOINS NEW SICKLE CELL DISEASE COALITION, ISSUES CALL TO ACTION TO IMPROVE TREATMENT AND CARE

Prolong Pharmaceuticals joins other leading patient advocacy groups, researchers, clinicians, policymakers, industry, and foundations in a collective effort to improve sickle cell disease (SCD) care, early diagnosis, treatment, and research, both in the United States and globally...

Prolong Pharmaceuticals Presents Data on Unique “Un-Sickling” In Vitro Activity Observed in Sickle Cell Investigational Drug SANGUINATE™

SOUTH PLAINFIELD, NJ, April 14, 2015 /PRNewswire/ -- Prolong announced today that it had presented data on its flagship product SANGUINATE, reporting its novel ability to rapidly reverse sickling of human red blood cells...

Prolong Pharmaceuticals’ Flagship Product SANGUINATE™ Granted Orphan Drug Designation by the FDA

SOUTH PLAINFIELD, N.J., April 8, 2015 /PRNewswire/ -- Prolong announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its flagship product SANGUINATE...

Prolong Pharmaceuticals Adds Industry Veteran Ronald Jubin To Executive Management Team

SOUTH PLAINFIELD, N.J., Dec. 18, 2013 /PRNewswire/ -- Prolong Pharmaceuticals LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and mortality, today announced...